Novel Monoclonal Antibodies
Oncology, Autoimmune Diseases
Pre-clinicalResearch
Key Facts
Indication
Oncology, Autoimmune Diseases
Phase
Pre-clinical
Status
Research
Company
About Changchun High-Tech Industry
Changchun High-Tech is a prominent, revenue-generating biopharmaceutical enterprise in China, primarily known for its vaccine business. Its strategic position is anchored by its controlling stake in Changchun BCHT Biotechnology, a critical supplier of the Varicella vaccine in the domestic market. The company leverages this established commercial foundation to invest in and develop a broader pipeline of biological products, including monoclonal antibodies and other innovative therapeutics. As a publicly listed entity, it operates with a diversified business model that also includes investments in real estate and other industries.
View full company profileOther Oncology, Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilars Pipeline | Laurus Labs | Development |
| Biosimilar (Rituximab) | Ipca Laboratories | Development |
| Biosimilar Candidates | China Resources Pharmaceutical Group | Phase 3 |
| Biosimilars (e.g., trastuzumab, rituximab) | Aspen Pharmacare | Approved |
| Biosimilar Pipeline (Confidential) | Gland Pharma | Development |